Nov. 10 at 5:06 PM
Shares of AnaptysBio Inc. dropped after the clinical-stage biotech company announced the suspension of its ulcerative colitis trial, as rosnilimab failed to meet key primary and secondary endpoints.
The company reported that while rosnilimab was found to be safe and well-tolerated, with adverse event rates similar to those of a placebo, it did not demonstrate sufficient efficacy at week 12 in the global Phase 2 trial for moderate-to-severe ulcerative colitis. The drug failed to achieve the primary endpoint of mean change from baseline in the modified Mayo score, as well as key secondary endpoints of clinical response and clinical remission.
Despite showing expected pharmacology, including a reduction of approximately 90% in pathogenic T cells, the efficacy results did not support further development in ulcerative colitis. AnaptysBio stated that halting the trial would save at least
$10 million.
$ANAB